JUNS$2.47+6.93%
Jupiter Neurosciences, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$3.26M
Float & O/S:
Inst Own:
DilutionScan read 38 of JUPITER NEUROSCIENCES, INC.'s SEC filings and found 2 warrant series, 3 convertibles, 1 equity line, 2 shelf registrations, 2 S-1 registrations and 7 completed offerings on file for JUNS. The latest dilution event on file is a registration statement on Sep 25, 2026. Analysis updated Oct 3, 2026.
Signal8 Summary
JUNS
Going-concern warning; zero cash runway
Snapshot
Jupiter Neurosciences is a clinical-stage biotech with essentially no revenue ($22K in FY 2025) and massive losses ($8.6M net loss). The company burns cash quickly ($5.4M in free cash flow annually) and holds only $3.8M in cash against $5.3M in debt, resulting in a cash runway of less than one month.
What's Happening Right Now
- : Jupiter signed a definitive agreement for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic, in a transaction valued up to $100 million.
- : The company is seeking stockholder approval for a reverse stock split between 1-for-10 and 1-for-100 to regain compliance with Nasdaq listing rules.
- : Jupiter closed a $2.0 million registered direct offering, issuing over 7 million shares to extend cash runway and pay down debt.
